BIOVIE INC.
BIVINext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for BIVI. That does not mean none is planned.
Get an email about BIVI's next catalysts
Track BIOVIE (BIVI) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 1 past
BIVI Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
How BIVI's past catalysts played out
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NE3107 | Phase 3 | Parkinsons Disease (PD) | - | - |
Terlipressin acetate continuous infusion | Phase 2 | Cirrhosis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in BIOVIE INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in BIOVIE INC.'s (BIVI) pipeline across Phase 3, Phase 2. Its lead program is NE3107 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BIOVIE INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for BIOVIE INC. (BIVI) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track BIVI biotech catalysts?→
Add BIVI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BIOVIE INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.